Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Prepaid Assets (2016 - 2025)

Iovance Biotherapeutics has reported Prepaid Assets over the past 13 years, most recently at $11.6 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $11.6 million for Q4 2025, down 6.42% from a year ago — trailing twelve months through Dec 2025 was $11.6 million (down 6.42% YoY), and the annual figure for FY2025 was $11.6 million, down 6.42%.
  • Prepaid Assets for Q4 2025 was $11.6 million at Iovance Biotherapeutics, up from $9.8 million in the prior quarter.
  • Over the last five years, Prepaid Assets for IOVA hit a ceiling of $17.5 million in Q4 2023 and a floor of $9.8 million in Q3 2025.
  • Median Prepaid Assets over the past 3 years was $11.8 million (2023), compared with a mean of $12.8 million.
  • Biggest five-year swings in Prepaid Assets: dropped 29.1% in 2024 and later soared 38.37% in 2025.
  • Iovance Biotherapeutics' Prepaid Assets stood at $17.5 million in 2023, then fell by 29.1% to $12.4 million in 2024, then dropped by 6.42% to $11.6 million in 2025.
  • The last three reported values for Prepaid Assets were $11.6 million (Q4 2025), $9.8 million (Q3 2025), and $11.5 million (Q2 2025) per Business Quant data.